Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.

NCT02346578 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

104

Enrollment

OTHER

Sponsor class

Conditions

Castration-resistant Prostate Cancer

Interventions

DRUG: Enzalutamide
DRUG: Flutamide

Sponsor

Taro Iguchi, MD, PHD

Collaborators

[object Object]